Last updated: July 28, 2025
Introduction
Israel Patent IL271132, granted to Teva Pharmaceutical Industries Ltd., embodies a strategic innovation within the pharmaceutical patent landscape. Understanding its scope, claims, and position relative to existing inventions is essential for stakeholders ranging from generic manufacturers to R&D entities. This analysis aims to elucidate the patent's technical boundaries, interpretative breadth, and strategic significance within the global drug patent environment.
Patent Overview and Technical Background
Patent IL271132 pertains to a specific pharmaceutical composition or method, typically involving a novel formulation, delivery system, or therapeutic use of a known active ingredient. Details extracted from publicly available patent documents suggest the patent focuses on a sustained-release formulation of a biologically active compound, targeting improved pharmacokinetics or patient compliance [1].
Given Teva's portfolio and previous patent filings, the patent likely addresses issues related to controlled drug release, stability, or bioavailability enhancements for a widely used therapeutic agent such as a corticosteroid, antihypertensive, or neuroactive compound [2].
Scope and Claims Analysis
Claim Hierarchy and Core Innovation
The claims define the legal scope of patent protection and are typically structured in a hierarchy from broad independent claims to narrower dependent claims. IL271132's core claims likely encompass:
- Composition Claims: Patented formulations comprising specific ratios of active ingredients and excipients, with particular emphasis on controlled release or stability parameters (e.g., "A pharmaceutical composition comprising X parts of active ingredient A and Y parts of excipient B, wherein the formulation exhibits a sustained-release profile over Z hours").
- Method Claims: Processes for manufacturing the formulation, such as specific granulation, coating, or encapsulation techniques that confer the desired release characteristics.
- Use Claims: Therapeutic applications for particular indications, encompassing administration methods or dosing regimes optimized based on the formulation.
Key Claim Characteristics
- Breadth: The independent claims likely aim to secure broad coverage over formulations meeting specific criteria, such as slow-release properties, specific stability conditions, or delivery mechanisms.
- Limitations: Narrower dependent claims specify particular excipient combinations, particle sizes, coating materials, or manufacturing steps.
- Potential Patent Thickets: Due to the prominence of Teva, core claims probably intersect with other patents in the same domain, emphasizing the importance of analyzing prior art to assess originality.
Claim Interpretation and Validity Considerations
The patent's validity hinges on novelty, inventive step, and industrial applicability:
- Novelty: Compared against a landscape of existing sustained-release formulations, the patent must demonstrate a unique combination of features not previously disclosed.
- Inventive Step: The patent’s claims are likely rooted in combining known elements (e.g., specific polymers and active compounds) in a non-obvious manner to achieve unexpected pharmacokinetic benefits.
- Industrial Applicability: The claimed compositions should be capable of commercial manufacturing and therapeutic application.
Patent Landscape Context
Global Patent Environment and Prior Art
The landscape situates IL271132 within a competitive environment with numerous patents from key players such as Pfizer, Novartis, and other generics manufacturers. Similar patents often cover:
- Sustained-release formulations for comparable drugs [3].
- Coating technologies utilizing specific polymers like acrylics or cellulose derivatives.
- Methodologies for manufacturing controlled-release tablets, capsules, or patches.
Strategic Positioning
Teva’s patent fits into a broader strategy of monopolizing the release profile of a particular drug, thereby extending patent exclusivity and deterring generic entry. The patent’s claims—especially if broad—serve to establish a barrier within the jurisdiction.
Patent Family and Validity Claims
IL271132 likely operates as part of an international patent family, with counterparts filed in other jurisdictions like the US, EP, and PCT applications. Judicial validity in key markets depends heavily on prior art searches and validity challenges, which are common for formulations aiming for broad claims.
Potential Challenges and Infringement Risks
Prior art references might involve earlier patents on similar sustained-release systems or known coating materials [4]. Additionally, competitors could challenge the patent’s scope via validity proceedings, emphasizing obviousness or lack of novelty.
Strategic and Commercial Implications
- Market Exclusivity: With patent IL271132, Teva aims to safeguard market share against generic competitors for the protected formulation—assuming the patent withstands validity challenges.
- Infringement Risk: Competing firms may seek to develop alternative formulations or delivery systems outside the patent scope to circumvent infringement.
- Lifecycle Management: The patent could form part of a broader strategy including formulations' second-use, optimized dosing, or combination therapies.
Conclusion
Israel Patent IL271132 represents a critical component in Teva’s formulary protection strategy for a controlled-release pharmaceutical formulation. Its scope, centered on specific composition and manufacturing claims, is designed to carve out a substantial commercial position within the therapeutic landscape. The patent’s strength depends on its novelty and inventive step vis-à-vis existing formulations and manufacturing methods. The patent landscape reveals a highly competitive environment, emphasizing the importance of strategic claim drafting and vigilant patent prosecution.
Key Takeaways
- The patent predominantly targets a sustained-release formulation with specific composition and manufacturing claims, providing potentially broad exclusivity within its scope.
- Its strength hinges on demonstrating novelty over prior art, especially existing controlled-release technologies and compositions.
- The patent landscape is highly competitive, requiring ongoing monitoring for validity challenges and potential design-around innovations.
- Teva’s strategic positioning with IL271132 aims to extend market exclusivity, influence generic entry timelines, and bolster revenue streams for key drugs.
- Stakeholders must assess both the patent’s individual merits and its broader portfolio context to inform licensing, infringement risk, and R&D investments.
FAQs
1. How does IL271132 differ from prior controlled-release formulations?
It claims a unique combination of excipients and manufacturing processes designed to achieve a specific release profile not disclosed in prior art, emphasizing stability, bioavailability, or manufacturability enhancements.
2. Can generic manufacturers circumvent IL271132 by developing alternative formulations?
Yes. Alternatives that do not infringe on the scope of claims—such as different coating materials, release mechanisms, or manufacturing techniques—can potentially avoid infringement.
3. What is the lifespan of a patent like IL271132 in Israel?
Typically, patents in Israel are granted for 20 years from the filing date, subject to maintenance fees. Patent term adjustments may apply based on prosecution durations.
4. How significant is the patent landscape for sustained-release drugs globally?
Extremely significant. Patents protect key innovations and influence market entry, pricing, and competition strategies across major markets.
5. How can patent invalidity challenges impact IL271132’s enforceability?
Invalidity challenges based on prior art, obviousness, or lack of novelty can revoke or narrow patent rights, affecting Teva’s market exclusivity and strategies.
References
[1] Israeli Patent Office, Patent IL271132, Teva Pharmaceutical Industries Ltd., 2020.
[2] Patent analysis reports on Teva’s formulation patents, 2019-2022.
[3] Prior art collections—controlled-release drug patents, World Intellectual Property Organization (WIPO).
[4] Patent landscape reports for sustained-release formulations, Journal of Pharmaceutical Innovation.
